Literature DB >> 29300888

Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation.

Lien Desteghe1,2, Johan Vijgen2, Pieter Koopman2, Dagmara Dilling-Boer2, Joris Schurmans2, Paul Dendale1,2, Hein Heidbuchel1,3.   

Abstract

Aims: To evaluate the effect of telemonitoring on adherence to non-vitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF) patients. Methods and results: A randomized, single-blind, crossover, controlled trial in 48 AF patients on once or twice daily (OD or BID) NOAC. The Medication Event Monitoring System tracked NOAC intake during three phases of 3 months each: daily telemonitoring, telemonitoring with immediate telephone feedback in case of intake errors, and an observation phase without daily transmissions. Unprotected days were defined as ≥ 3 or ≥ 1 consecutively missed doses for a BID or OD NOAC, respectively, or excess dose intake. Cost-effectiveness was calculated based on anticipated stroke reduction derived from patients' risk profile and measured intake. Persistence over the entire study was 98%. Telemonitoring-only already led to very high taking and regimen adherence (97.4% respectively 93.8%). Nevertheless, direct feedback further improved both to 99.0% and 96.8%, respectively (P < 0.001 respectively P = 0.002). Observation without daily monitoring resulted in a significant waning of taking adherence (94.3%; P = 0.049). Taking adherence was significantly higher for OD compared to BID NOAC, although unprotected days were similar. Feedback intervention had an incremental cost of €344 289 to prevent one stroke, but this could be as low as €15 488 in high-risk patients with low adherence and optimized technology.
Conclusion: Telemonitoring resulted in high NOAC adherence due to the notion of being watched, as evidenced by the rapid decline during the observation period. Feedback further optimized adherence. Telemonitoring with or without feedback may be a cost-effective approach in high-risk patients deemed poorly adherent.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29300888     DOI: 10.1093/eurheartj/ehx762

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  11 in total

1.  The temporal context of oral anticoagulation outcome in atrial fibrillation.

Authors:  Anke C Fender; Dobromir Dobrev
Journal:  Int J Cardiol Heart Vasc       Date:  2022-05-13

2.  Impact of the COVID-19 lockdown on the adherence of stroke patients to direct oral anticoagulants: a secondary analysis from the MAAESTRO study.

Authors:  Fine Dietrich; Alexandros A Polymeris; Isabelle Arnet; Philippe A Lyrer; Melina Verbeek; Stefan T Engelter; Kurt E Hersberger; Sabine Schaedelin
Journal:  J Neurol       Date:  2021-06-03       Impact factor: 4.849

3.  Factors Associated with Anticoagulation Adherence in Chinese Patients with Non-Valvular Atrial Fibrillation.

Authors:  Ting Song; Xiao Xin; Peirong Cui; Mingcan Zong; Xianhua Li
Journal:  Patient Prefer Adherence       Date:  2021-03-01       Impact factor: 2.711

4.  Can nurses help improve self-care of patients living with atrial fibrillation? A focus group study exploring patients' disease knowledge gaps.

Authors:  Tammy R Toscos; Amanda Coupe; Shauna Wagner; Michelle Drouin; Amelia E Roebuck; Carly N Daley; Maria D Carpenter; Michael J Mirro
Journal:  Nurs Open       Date:  2020-05-12

Review 5.  Antithrombotic therapies for elderly patients: handling problems originating from their comorbidities.

Authors:  Masahisa Arahata; Hidesaku Asakura
Journal:  Clin Interv Aging       Date:  2018-09-11       Impact factor: 4.458

Review 6.  On-demand mobile health infrastructures to allow comprehensive remote atrial fibrillation and risk factor management through teleconsultation.

Authors:  Astrid N L Hermans; Rachel M J van der Velden; Monika Gawalko; Dominique V M Verhaert; Lien Desteghe; David Duncker; Martin Manninger; Hein Heidbuchel; Ron Pisters; Martin Hemels; Laurent Pison; Afzal Sohaib; Arian Sultan; Daniel Steven; Petra Wijtvliet; Robert Tieleman; Dhiraj Gupta; Dobromir Dobrev; Emma Svennberg; Harry J G M Crijns; Nikki A H A Pluymaekers; Jeroen M Hendriks; Dominik Linz
Journal:  Clin Cardiol       Date:  2020-10-08       Impact factor: 2.882

7.  A new smartphone application for integrated transmural care of atrial fibrillation, AF-EduApp: Usability and validation study.

Authors:  Lieselotte Knaepen; Michiel Delesie; Rik Theunis; Johan Vijgen; Paul Dendale; Lien Desteghe; Hein Heidbuchel
Journal:  Digit Health       Date:  2021-12-23

8.  A Smartphone App to Improve Oral Anticoagulation Adherence in Patients With Atrial Fibrillation: Prospective Observational Study.

Authors:  Keitaro Senoo; Tomonori Miki; Takashi Ohkura; Hibiki Iwakoshi; Tetsuro Nishimura; Hirokazu Shiraishi; Satoshi Teramukai; Satoaki Matoba
Journal:  JMIR Mhealth Uhealth       Date:  2022-01-07       Impact factor: 4.773

9.  Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation.

Authors:  José Maria Farinha; Ian D Jones; Gregory Y H Lip
Journal:  Eur Heart J Suppl       Date:  2022-02-14       Impact factor: 1.803

10.  Rationale design and efficacy of a smartphone application for improving self-awareness of adherence to edoxaban treatment: study protocol for a randomised controlled trial (adhere app).

Authors:  In-Cheol Kim; Ji Hyun Lee; Dong-Ju Choi; Sung-Ji Park; Ju-Hee Lee; Sang Min Park; Mina Kim; Hack-Lyoung Kim; Sunki Lee; In Jai Kim; Seonghoon Choi; Jaehun Bang; Bilal Ali; Musarrat Hussain; Taqdir Ali; Sungyoung Lee
Journal:  BMJ Open       Date:  2022-04-27       Impact factor: 3.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.